Modulatory Effect of Gliadin Peptide 10-mer on Epithelial Intestinal CACO-2 Cell Inflammatory Response

Antonella Capozzi1,*, Olimpia Vincentini2,*, Pietro Gizzi1, Alessandra Porzìa1, Agostina Longo1, Cristina Felli2, Vincenzo Mattei3, Fabrizio Mainiero1, Marco Silano2, Maurizio Sorice1, Roberta Misasi1*

1 Department of Experimental Medicine, Sapienza University, Rome, Italy, 2 Unit of Human Nutrition and Health, Istituto Superiore di Sanità, Rome, Italy, 3 Experimental Medicine and Environmental Pathology Laboratory, “Sapienza” University, Rieti, Italy

Abstract

Celiac Disease (CD) is a chronic inflammatory enteropathy, triggered in genetically susceptible individuals by dietary gluten. Gluten is able to elicit proliferation of specific T cells and secretion of inflammatory cytokines in the small intestine. In this study we investigated the possibility that p10-mer, a decapeptide from durum wheat (QQQQRADVQPF), which was previously shown to prevent the activation of celiac peripheral lymphocytes, may exert an inhibitory effect on peptic-tryptic digested gliadin (PT-Gly)-stimulated intestinal carcinoma CACO-2 cells. In these cells, incubated with PT-Gly or p31-43 α-gliadin derived peptide in the presence or in the absence of p10-mer, IRAK1 activation and NF-kB, ERK1/2 and p38 MAPK phosphorylation were measured by immunoblotting, Cyclooxygenase 2 (COX-2) activity by PGE-2 release assay, and production of cytokines in the cell supernatants by ELISA. Our results showed that pre-treatment of CACO-2 cells with p10-mer significantly inhibited IRAK1 activation and NF-kB, ERK1/2 and p38 MAPK phosphorylation, as well as COX-2 activity (i.e., PGE-2 release) and production of the IL-6 and IL-8 pro-inflammatory cytokines, induced by gliadin peptides. These findings demonstrate the inhibitory effect of the p10-mer peptide on inflammatory response in CACO-2 cells. The results of the present study show that this p10-mer peptide can modulate “in vitro” the inflammatory response induced by gliadin peptides, allowing to move towards new therapeutic strategies. Turning off the inflammatory response, may in fact represent a key target in the immunotherapy of celiac disease.

Introduction

Celiac disease (CD) is a chronic inflammatory enteropathy with an autoimmune pathogenesis, triggered in genetically susceptible individuals by dietary gluten, the alcohol protein fraction of cereals, such as wheat, rye and barley. Gliadin is the main protein from wheat gluten. CD is histologically characterized by villous atrophy, crypt cell hyperplasia and increased number of intraepithelial lymphocytes. In addition, patients with celiac disease typically develop antibodies to gliadin and autoantibodies specific for endogenous enzyme transglutaminase 2 (TG2) [1]. At present, many gluten peptides have been described to elicit proliferation and secretion of cytokines, such as interferon-γ, of gluten specific T cells in the intestinal mucosa of CD patients [2,3]. Susceptibility to celiac disease is strongly associated with major histocompatibility complex (MHC) class II molecules, HLA-DQ2 and HLA-DQ8. In particular, the immune response, directed against specific gluten antigens, leads to destruction of intestinal epithelial cells (IECs).

Although gluten is known to play a role in activating gluten-specific T cells in the lamina propria, recent evidences support the notion that gluten affects the innate immune response [4–6]. Thus, both innate and adaptive immune responses are necessary to trigger the gluten-dependent mucosal inflammation [7]. Indeed, the α-gliadin-derived peptide p31–43 is able to activate the innate immune response in celiac mucosa. Moreover, the activation of the mucosal innate immunity by p31–43 has been demonstrated to be required to trigger the immunogenicity of p33-mer, another α-gliadin derived peptide [8–10].

Activation of intestinal epithelial cells plays a pivotal role in CD pathogenesis [8] mediating gut inflammation. Intestinal epithelial cells represent an important component of innate immunity and activate sophisticated responses to inflammatory stimuli. The manner in which intestinal epithelial cell polarity affects responses to inflammatory stimuli is largely unknown, but it is clear that intestinal epithelial cells actively participate in directing an inflammatory response [11]. Although the vast majority of bacterial and food components do not elicit intestinal inflammation, it is known that pathogens that cause acute inflammation do activate the NF-kB pathway, resulting in a regulation of genes encoding proinflammatory cytokines, chemokines and adhesion molecules [11,12].

At present, the only known treatment of CD is the life-long withdrawal of gluten containing food from the diet.

We described p10-mer, a decapptide (sequence QQQQRADVQPF) [13] that prevents the activation of peripheral celiac lymphocytes by gliadin peptides [14] and promotes a shift...
from a Th1-type response toward a Th2-type response in celiac disease [15]. In the present study we evaluated "in vitro" the modulating effect of p10-mer on gliadin-triggered intestinal epithelial cell inflammation. Our results indicated first that this peptide is able to prevent IRAK1 and NF-kB activation, induced by gliadin peptides, in intestinal Caco-2 cells.

Materials and Methods

Cell culture

Caco-2/TC7 cells [16] were cultured in Dulbecco’s Modified Medium (high glucose) supplemented with 1% non-essential amino acids and containing 10% fetal calf serum (FCS); 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and 1 mM Hepes (Invitrogen, Carlsbad, CA, USA) at 37°C in a humified 5% CO₂ atmosphere. The culture medium was replaced three times a week. Subculture was performed at 80% of confluence. All experiments were performed between passages 65 and 78.

Gliadin preparation and peptic-triptic digestion

The peptic-triptic digest of gliadin (PT-Gly) is a useful tool to study the biological effects of gliadin. The PT-Gly contains some gliadin peptides that show different toxic activity in CD patients tissues. The alcohol-soluble protein fraction from whole cereal flour of bread wheat (Triticum aestivum, variety S Pastore) was extracted and subjected to peptic-triptic digestion, as previously described [14,17]. Briefly, gliadin was separated from wheat flour by a 70% ethanol aqueous solution. Then, gliadin was exposed at 37°C to pepsin (Sigma Chem Co, St. Louis, MO USA), for 2 hours pH 2.0 and, then, to trypsin (Sigma) for 4 hours pH 8.0. Afterwards, the incubation was stopped adjusting pH to 7.0 and the samples were lyophilized and stored at −20°C until used. Gliadin preparation was assayed for endotoxin by using a reagent kit (QCL-100; BioWhittaker, Walkersville, MD USA); they were found to have endotoxin concentrations <0.5 enzymatic U/ml.

Peptide preparation

The sequence p10-mer (QQPQDAVQPF; MW = 1157 D) and biotinylated gliadin peptide p31–43 (LGQQQPFPPQQPYPQPQPF) were synthesized (Primm Company, Milano, Italy) by the solid-phase method (model 431A; Applied Biosystems, Foster City, CA, USA) and purified up to 99% with the use of reverse phase HPLC (5020 system; Varian Inc, Walnut Creek, CA, USA). Peptides were used in the experiments at a concentration of 50 μg/ml.

Preparation of cell extracts

Caco-2 cells were pre-treated for 1 hour with p10-mer (50 μg/ml) and then stimulated with PT-Gly (1 mg/ml) or p10-mer, p10-mer+PT-Gly, p31–43, p10-mer+p31–43 were separated in 7.5% SDS-PAGE under reducing conditions and electrophoresed by the use of mini Protein II Dual Slab Cell. The proteins were electrophoretically transferred to PVD film (Bio-Rad Lab.) and then, after blocking with PBS, containing 1% albumin, probed with polyclonal anti-phospho-IRAK1 (Cell Signalling, Inc, Danvers, MA, USA), polyclonal anti-phospho-NF-kB p65 (Cell Signalling, Inc), polyclonal anti-phospho-ERK1/2 (Cell Signalling, Inc), polyclonal anti-phospho-p38 (Cell Signalling, Inc) or monoclonal anti-cyclooxygenase 2 (COX-2) antibodies (Abcam, Cambridge, UK). Bound antibodies were visualized with HRP-conjugated anti-rabbit IgG or anti-mouse IgG (Sigma). As a control for nonspecific reactivity, parallel SDS-PAGE gels were blotted as described, using an anti-rabbit IgG or anti-mouse IgG (Sigma). As a control for loading of preparation, IRAK1, phospho-NF-kB p65, phospho-ERK1/2, phospho-p38 and COX-2 blotted membranes were stripped and reprobed with monoclonal anti-α-tubulin (Sigma) and with polyclonal anti-IRAK1 (Cell Signalling, Inc), anti-NF-kB p65 (Cell Signalling, Inc), anti-ERK1/2 (Cell Signalling, Inc) or anti-p38 (Cell Signalling, Inc) antibodies, respectively.

Analysis of Cyclooxygenase 2 activity by PGE-2 production

Brieﬂy, Caco-2/TC7 cells were seeded in 6 wells plates at a density of 500×10⁶ cells and cultured for five days. Cells were then incubated in medium containing 0.5% FBS in the presence or in the absence of p10-mer peptide, as pre-treatment for 1 hour and then stimulated with PT-Gly for 24 hours at 37°C. At the end of the treatment, the culture medium was collected and centrifuged to remove particulates, then stored at −80°C. The PGE-2 concentration released in the sample was quantified using a PGE-2 assay kit (Cayman, Ann Arbor, MI, USA) according to manufacturer’s protocol. Supernatants were diluted in a 5-fold dilution to ensure the concentrations of PGE-2 present in the samples were within the linear range of the standard curve for the assay. The PGE-2 concentration of each sample was determined according to the standard curve.

Cytokine determination

Cells were stimulated as described above for 24 hours at 37°C. After treatment, cell supernatants were collected and frozen at −80°C until analysis. Production of the pro-inflammatory cytokines IL-6 and IL-8 was measured in the cell supernatants using an enzyme-linked immunosorbent assay (ELISA) (Bender MedSystems, San Diego, CA, USA) and quantified using a reference standard curve provided with the kit. The experiments were performed in triplicate for three times.

Cellular supernatants from unstimulated or stimulated Caco-2/TC7 cells with PT-Gly, p10-mer or p10-mer+PT-Gly were tested for IL-17 concentration by enzyme-linked immunosorbent assay (ELISA), using a commercially available ELISA kit (R&D Systems, Inc., Minneapolis, MN, USA), according to the manufacturer’s instruction. Simultaneously, unstimulated or stimulated Caco-2/TC7 cells with PT-Gly, p10-mer or PT-Gly+p10-mer were washed with phosphate-buffered saline, fixed with 2% paraformaldehyde for 20 min, permeabilized with 0.5% Triton X-100 and stained with the monoclonal antibody anti-IRAK1, phospho-NF-kB p65, phospho-ERK1/2, phospho-p38 and COX-2 antibodies (Abcam, Cambridge, UK). Bound antibodies were visualized with HRP-conjugated anti-rabbit IgG or anti-mouse IgG (Sigma). As a control for nonspecific reactivity, parallel SDS-PAGE gels were blotted as described, using an anti-rabbit IgG or anti-mouse IgG (Sigma). As a control for loading of preparation, IRAK1, phospho-NF-kB p65, phospho-ERK1/2, phospho-p38 and COX-2 blotted membranes were stripped and reprobed with monoclonal anti-α-tubulin (Sigma) and with polyclonal anti-IRAK1 (Cell Signalling, Inc), anti-NF-kB p65 (Cell Signalling, Inc), anti-ERK1/2 (Cell Signalling, Inc) or anti-p38 (Cell Signalling, Inc) antibodies, respectively.

Western blot analysis

Equal amounts of whole cellular extract [from unstimulated or stimulated Caco-2/TC7 cells with PT-Gly, p10-mer, PT-Gly+p10-mer, p10-mer+PT-Gly, p31–43, p10-mer+p31–43 were separated in 7.5% SDS-PAGE under reducing conditions and electrophoresed by the use of mini Protein II Dual Slab Cell. The proteins were electrophoretically transferred to PVD membrane (Bio-Rad Lab.) and then, after blocking with PBS, containing 1% albumin, probed with polyclonal anti-phospho-IRAK1 (Cell Signalling, Inc, Danvers, MA, USA), polyclonal anti-phospho-NF-kB p65 (Cell Signalling, Inc), polyclonal anti-phospho-ERK1/2 (Cell Signalling, Inc), polyclonal anti-phospho-p38 (Cell Signalling, Inc) or monoclonal anti-cyclooxygenase 2 (COX-2) antibodies (Abcam, Cambridge, UK). Bound antibodies were visualized with HRP-conjugated anti-rabbit IgG or anti-mouse IgG (Sigma). As a control for nonspecific reactivity, parallel SDS-PAGE gels were blotted as described, using an anti-rabbit IgG or anti-mouse IgG (Sigma). As a control for loading of preparation, IRAK1, phospho-NF-kB p65, phospho-ERK1/2, phospho-p38 and COX-2 blotted membranes were stripped and reprobed with monoclonal anti-α-tubulin (Sigma) and with polyclonal anti-IRAK1 (Cell Signalling, Inc), anti-NF-kB p65 (Cell Signalling, Inc), anti-ERK1/2 (Cell Signalling, Inc) or anti-p38 (Cell Signalling, Inc) antibodies, respectively.
saponin/1% fetal calf serum, and stained with anti-IL-17A PE (Phycoeritrine) mAb for 30 min at 4 °C. Control cell samples were stained with IgG1 PE. Both mAbs were obtained from Biosciences (San Diego, CA, USA). Cells then were analyzed with a FACSCalibur (BD Biosciences, San José, California, USA), using FlowJo (Treestar, Ashland, OR, USA) software. The percentage of IL-17 producing cells was obtained by setting the lower limit on the basis of a matched isotype IgG1 PE control mAb-stained sample, whose positivity never exceeded 0.5% of gated events.

**Immunofluorescence and flow cytometry analysis of p31-43 expression**

Caco-2 cells were grown to 60–70% confluence, seeded on μ-Slide 8 well (Ibidi, Martinsried, Germany) and used for an indirect immunofluorescence assay. Confluent cells were pre-treated for 1 hour with p10-mer (50 μg/ml) and then incubated for 10 min with biotinylated p31–43 (50 μg/ml). Cells were then washed with PBS and fixed with paraformaldehyde 4% in PBS for 30 minutes at room temperature, permeabilized with 0.05% Triton-x100 in PBS for 5 min at room temperature and stained with streptavidin-Alexafluor 488 488 (1:400) (Life Technologies, Paisley, UK). The cells were washed for 3 times with PBS and slides were mounted in glycerol/Tris-HCl pH 9.2 (3:1) and observed at the microscope. The images were acquired using an Olympus U RFL microscope (Olympus, Hamburg, Germany). The images were collected at 512x512 pixels, processed and filtered to minimize background noise.

For cytofluorimetric analysis cells were seeded at a density of 5x10^5 on 6 wells plates, and pre-treated at confluence with p10-mer (50 μg/ml) for 1 hour and then with biotinylated p31–43 (50 μg/ml) for 10 min. At the end of the treatments cells were detached by the use of trypsin and washed with PBS, fixed with paraformaldehyde 4% in PBS for 30 min at room temperature and permeabilized with 0.05% Triton-x100. Cells were incubated with streptavidin-Alexafluor 488 (1:400), washed with PBS and analysed by a BD FACSCalibur flow cytometer (Becton Dickinson Biosciences), using FlowJo (Treestar) software.

**Statistics**

All the statistical procedures were performed by SAS/STAT Software provided by SAS Institute Inc. (Cary, North Carolina, USA). P values have been calculated with the T-Student test and P values less than 0.05 were considered as significant.

**Results**

**Inhibitory effect of gliadin peptide 10-mer on PT-Gly activated Caco-2 cells**

Since CD is an autoimmune permanent disease supported by an inflammatory environment [4], in this study we analyzed the putative gliadin-dependent signaling pattern leading to inflammation. Cell lysates from Caco-2 cells, either unstimulated or stimulated with PT-Gly, p10-mer, p10-mer+PT-Gly, were analyzed by Western blot for IRAK1 phosphorylation and NF-κB activation. As expected, the results in Fig. 1A showed that PT-Gly induced IRAK1 phosphorylation, as revealed by anti-phospho-IRAK1 reactivity. When the cells were stimulated with PT-Gly (45 min) after pre-treatment with p10-mer, IRAK1 phosphorylation appeared reduced.

With the aim to verify IRAK1 activation pathway, that is known to lead to the activation of NF-κB [12], we investigated the effects of p10-mer on PT-Gly-induced p65 NF-κB activation. As expected, Western blot analysis of cell lysates revealed that PT-Gly stimulation (for 45 min) induced p65 activation, as revealed by anti-phospho-NF-κB p65 Ser reactivity (Fig. 1B). On the contrary, cells stimulated with PT-Gly after pre-treatment with p10-mer revealed phospho-NF-κB p65 levels virtually comparable to control cells. Cell lysates obtained using non IRAK1 and non NF-κB p65-specific IgG yielded no reactivity (data not shown).

The same cell lysates tested for IRAK1 phosphorylation and p65 NF-κB activation were also analyzed by anti-phospho-ERK1/2 and anti-phospho-p38 antibodies. As shown in Fig. 2, ERK (Fig. 2A) and p38 MAPK (Fig. 2B) phosphorylation was evident in cell lysates from Caco-2 cells treated with PT-Gly (for 10 min); as shown, the same effector did not induce ERK and p38 MAPK phosphorylation after pre-treatment with p10-mer.

![Figure 1. Inhibitory effect of gliadin peptide 10-mer on IRAK1 phosphorylation and NF-κB activation.](image-url)
Gliadin peptide 10-mer modulates COX-2 expression and activity in PT-Gly-stimulated CACO-2 cells

Since pro-inflammatory stimuli, often converging to the activation of ERK1/2 [18], promote COX-2 regulation, we preliminary investigated COX-2 expression in PT-Gly-treated cells. CACO-2 cells were pre-treated with p10-mer before PT-Gly treatment (for 3 hours). In Fig. 3A Western blot and densitometric analyses show that, when cells were pre-treated with p10-mer, a partial inhibition of COX-2 expression occurred. Since COX-2 can be regulated at transcriptional as well as post-transcriptional level, we analyzed the modulation of COX-2 enzymatic activity by measuring PGE-2 release in CACO-2 cells pre-treated with p10-mer and then stimulated with PT-Gly for 24 hours. p10-mer significantly inhibited PGE-2 production (P<0.05) (Fig. 3B).

Effect of gliadin peptide 10-mer on cytokines production by PT-Gly activated CACO-2 cells

Since activation of signal transduction molecules, such as IRAK, NF-κB and MAPK is known to elicit cytokine gene expression, we analyzed IL-6 and IL-8 production in CACO-2 cells after PT-Gly stimulation for 24 hours, in the presence or in

Figure 2. Inhibitory effect of gliadin peptide 10-mer on ERK and p38 MAPK phosphorylation. CACO-2/TC7 cells either unstimulated or stimulated with PT-Gly (1mg/ml), p10-mer (50 μg/ml), p10-mer (50 μg/ml) + PT-Gly (1mg/ml), were analyzed by Western blot for ERK and p38 phosphorylation. Phosphorylated levels of ERK were analyzed in whole cell extracts by Western blot with anti-phospho-ERK1/2 antibodies; for control, the blotted membranes were stripped and reprobed with anti-ERK1/2 antibodies. Bound antibodies were visualized with HRP-conjugated IgG and immunoreactivity was assessed by ECL. (B) Phosphorylated levels of p38 MAPK were analyzed in whole cell extracts by Western blot with anti-phospho-p38 MAPK antibodies; for control, the blotted membranes were stripped and reprobed with anti-p38 MAPK antibodies. Bound antibodies were visualized with HRP-conjugated IgG and immunoreactivity was assessed by ECL. Densitometric analysis was performed using ImageJ version 1.46 software and peaks were reproduced by reading the Western Blot bands. One example representative of 3 experiments.

doi:10.1371/journal.pone.0066561.g002

Figure 3. Regulatory effect of gliadin peptide 10-mer on COX-2 expression and activity in PT-Gly-stimulated CACO-2/TC7 cells. (A) CACO-2/TC7 cells, either unstimulated or stimulated with PT-Gly (1mg/ml), p10-mer (50 μg/ml), p10-mer (50 μg/ml) + PT-Gly (1mg/ml), were analyzed by Western blot for COX-2 expression. COX-2 expression was analyzed in whole cell extracts by Western blot with anti-COX-2 antibodies; for control, the blotted membranes were stripped and reprobed with anti-α tubulin antibodies. Bound antibodies were visualized with HRP-conjugated IgG and immunoreactivity was assessed by ECL. Densitometric analysis was performed using ImageJ version 1.46 software and peaks were reproduced by reading the Western Blot bands. (B) CACO-2/TC7 cells, either unstimulated or stimulated with PT-Gly (1mg/ml), p10-mer (50 μg/ml), p10-mer (50 μg/ml) + PT-Gly (1mg/ml) were analyzed for COX-2 enzymatic activity by measuring PGE-2 release with PGE-2 assay kit. Statistical analysis: *P<0.01 versus control; $P<0.05 versus PT-Gly. Results are expressed as mean ± SD; n = 3.

doi:10.1371/journal.pone.0066561.g003
discussed for years. However, p31–43 after pre-treatment with p10-mer revealed phospho-NF-κB p65 levels virtually comparable to control cells (Fig. 5A, i).

Similar findings were found on ERK phosphorylation. As shown in Fig. 5B, ERK phosphorylation was evident in cell lysates from CACO-2 cells treated with p31–43 (for 10 min); after pre-treatment with p10-mer, ERK phosphorylation was reduced, as revealed by densitometric analysis (Fig. 5A, ii).

Then, the entrance in the cell of the p31–43 was evaluated in the presence or in the absence of pre-treatment with the p10-mer. Our results strongly suggest that the p10-mer decapeptide is an inhibitor of the gliadin peptide entrance in the cell, as revealed by both flow cytometry (Fig. 5B) and immunofluorescence analysis (Fig. 5C).

Discussion

It has been reported that gliadin sequence contains at least two immunological triggers, the antigenic epitopes (p33mer) and the danger signal, which leads to the activation of the innate immune system (p31–43), the so-called “double soul of gliadin” [21]. The induction of an epithelial pro-inflammatory phenotype may alter the first mucosal defence against ‘toxic’ agents, leading to a wide perturbation of the regulatory mechanisms at the mucosal surface. The epithelial uptake of some toxic gliadin peptides, in particular p31–43, induces an intracellular pro-oxidative environment, favouring TG2 activation and leading to the innate immune response [10]. The inhibition of activation of the innate immune response in celiac disease might therefore be a useful therapeutic strategy to control disease evolution.

In this study, we investigated the ability to modulate the epithelial intestinal early response in celiac disease by a decapeptide (p10-mer, QQPQDAVQPF), already described to prevent activation of celiac peripheral lymphocytes by gliadin peptides and to down-regulate the adaptive immune response towards wheat prolamin [15].

Our results indicated first that this peptide is able to prevent IRAK1 phosphorylation and the consequent NF-κB activation, both induced by gliadin derived peptides, in CACO-2 cells. Moreover, when PT-Gly stimulated cells were pre-treated with p10-mer, a partial inhibition of both COX-2 protein expression and activation occurred.

It has been recently demonstrated that gliadin markedly activates immune cells, inducing the production of pro-inflammatory cytokines in all individuals, regardless of the clinical condition [22]. As expected [19], PT-Gly stimulation in CACO-2 cells induced secretion of two key pro-inflammatory cytokines, such as IL-6 and IL-8. In this regard, it is known that IL-8 is produced by stressed CACO-2 cells or gliadin-activated dendritic cells and it results overexpressed in response to dietary gluten [23]. IL-8 leads to a perturbation of the intracellular oxidative status in intestinal epithelial cells that reduces the production of PPAR-γ and elicits the NF-κB pathway activation [24]. Both these events play a key role in starting the inflammation in celiac epithelium. When cells were pre-treated for 1 hour with p10-mer peptide, a down-modulation of IL-6 and IL-8 secretion was evident.

The present study, using an intestinal epithelial cell line (CACO-2/TC7 cells), stimulated with the PT-Gly, also shows that pre-treatment with p10-mer peptide inhibited signal transduction pathway involving the IRAK1 kinase, resulting in inhibition of the activation cascade from the cytoplasm to the nuclear compartment. It is important in this context to point out that pre-treatment with p10-mer partially inhibited the up-regulation of the COX-2 protein, a finding that is in line with the results of previous studies [22].

It is noteworthy that gliadin was shown to be efficiently absorbed by Caco-2 monolayers [25, 26]. The gliadin peptides present in the small intestine are degraded by the action of proteases and the resulting peptides can enter the epithelial cells. This mechanism might play a key role in the development of celiac disease, as demonstrated by the fact that peptide absorption is increased in celiac disease [27].

In conclusion, these results strongly support the use of gliadin decapeptide in the treatment of celiac disease by a therapeutic strategy that could be compared to the use of the short chain fatty acids (SCFA) in the treatment of inflammatory bowel disease (IBD) [28]. Further studies are warranted to investigate the mechanisms underlying the inhibitory effect of the p10-mer decapeptide on celiac disease.

The present study, using an intestinal epithelial cell line (CACO-2/TC7 cells), stimulated with the PT-Gly, also shows that pre-treatment with p10-mer peptide inhibited signal transduction pathway involving the IRAK1 kinase, resulting in inhibition of the activation cascade from the cytoplasm to the nuclear compartment. It is important in this context to point out that pre-treatment with p10-mer partially inhibited the up-regulation of the COX-2 protein, a finding that is in line with the results of previous studies [22].

It is noteworthy that gliadin was shown to be efficiently absorbed by Caco-2 monolayers [25, 26]. The gliadin peptides present in the small intestine are degraded by the action of proteases and the resulting peptides can enter the epithelial cells. This mechanism might play a key role in the development of celiac disease, as demonstrated by the fact that peptide absorption is increased in celiac disease [27].

In conclusion, these results strongly support the use of gliadin decapeptide in the treatment of celiac disease by a therapeutic strategy that could be compared to the use of the short chain fatty acids (SCFA) in the treatment of inflammatory bowel disease (IBD) [28]. Further studies are warranted to investigate the mechanisms underlying the inhibitory effect of the p10-mer decapeptide on celiac disease.
nucleus. In particular, there was a reduced activation of transcription factors, such as NF-κB, resulting in inhibition or reduced production of inflammatory mediators [3]. Moreover, p10-mer is also able to prevent COX-2 enzymatic activity, with consequent PGE-2 release, induced by PT-Gly. Increased levels of PGE-2 were described in the mucosa of celiac patients [25]. In particular, PGE-2 has been described to increase the intestinal paracellular permeability [26]. COX-2, which may be regulated by TLR/Myd88 dependent signals, as well as by Th1 cytokines, is known to promote inflammation via prostaglandins, including PGE-2. However, TNF-α-induced COX-2 expression and activity depend heavily on activation of ERK 1/2 and NF-κB [18]. Interestingly, in the present study we demonstrated that also ERK 1/2 phosphorylation induced by gliadin derived peptides was prevented by pre-treatment with p10-mer, further supporting the hypothesis that this peptide exerts an inhibitory effect on inflammatory response in CACO-2 cells.

In order to clarify the mechanism by which p10-mer is able to prevent the proinflammatory activity of gliadin peptide, it would be important to know if p10-mer may act as inhibitor of the entrance of the gliadin peptide in the cell. In this regard, the entrance in the cell of the 31–43 α-gliadin peptide was evaluated in the presence or in the absence of pre-treatment with the p10-mer. Our results strongly suggest that the p10mer decapeptide is an inhibitor of the entrance of the gliadin peptide in the cell. Our findings on the effects of p10-mer on proinflammatory effects of gliadin peptides are consistent with previous observations by some of these authors, suggesting that p10-mer, and its naturally occurring–related peptide pRPQ, prevents some gliadin-dependent inflammatory pathways in intestinal epithelial cells and small bowel mucosa [27].

So far, the only known treatment for CD is the life-long exclusion of gluten-containing food from the diet or, alternatively, modifying the gluten sequences that act as epitopes in CD to

Figure 5. Effect of gliadin peptide 10-mer on p31–43 activity and entrance in CACO-2 cells. (A) CACO-2/TC7 cells, either unstimulated or stimulated with p31–43 (50 μg/ml), p10-mer (50 μg/ml) + p31–43 (50 μg/ml), were analyzed by Western blot for ERK phosphorylation and NF-κB activation. (i) Phosphorylated levels of ERK were analyzed in whole cell extracts by Western blot with anti-phospho-ERK1/2 antibodies; for control, the blotted membranes were stripped and reprobed with anti-ERK1/2 antibodies. Bound antibodies were visualized with HRP-conjugated IgG and immunoreactivity was assessed by ECL. (ii) NF-κB activation was analyzed in whole cell extracts by Western blot with anti-phospho-NF-κB p65 Ser antibodies; for control, the blotted membranes were stripped and reprobed with anti-NF-κB p65 antibodies. Bound antibodies were visualized with HRP-conjugated IgG and immunoreactivity was assessed by ECL. Densitometric analysis was performed using ImageJ version 1.46 software, peaks were reproduced by reading the Western Blot bands. One example representative of 3 experiments. (B) CACO-2/TC7 cells, either unstimulated or stimulated with biotinylated p31–43 (50 μg/ml), p10-mer (50 μg/ml) + biotinylated p31–43 (50 μg/ml), were immunostained with streptavidin-AlexaFluor and analyzed by a BD FACSCalibur flow cytometer. (C) CACO-2/TC7 cells, either unstimulated or stimulated with biotinylated p31–43 (50 μg/ml), p10-mer (50 μg/ml) + biotinylated p31–43 (50 μg/ml), were immunostained with streptavidin-AlexaFluor. The images were acquired using an Olympus U RFL fluorescence microscope. doi:10.1371/journal.pone.0066561.g005
abolish their immunogenic ability. Many approaches have been attempted to decrease the noxious effect of gluten in CD patients, such as degradation of gluten by exogenous enzymes [20], complexing gliadins in the gut by the use of polymeric binders diminishing the formation of immunogenic peptide [29], “scaling” tight junctions by the use of modulator of paracellular permeability to prevent the opening of tight junctions and restrict the passage of gluten peptides [30], interfering with immune recognition by the inhibition of tissue TG2 [31] or blockage of human leukocyte antigen (HLA) molecules [32] modulation of immune responses by peptide vaccination [33] and interference with inflammatory cell recruitment [34]. An alternative therapeutic option may rely on the reduction of the proinflammatory response induced by gliadin-derived molecules.

It has been already published [8] that inhibition of MAP kinase pathways can also be an effective approach in controlling the pathogenic cascade of celiac disease, showing that within the gliadin sequence there are at least two immunological triggers: the antigenic one, and the danger signal which leads to the activation of the innate immune system. This hypothesis may suggest that the inhibition of activation of the innate immune system in celiac disease might therefore be a useful therapeutic strategy to control disease evolution.

p10-mer has been described in the gluten sequence of a cereal cultivar only and the D and A residues, which confer the immunomodulatory activity to this peptide ([13, 15]), are very rare in the published gliadin sequences. However, we should not neglect the possibility that the sequence of p10-mer could be introgressed in a toxic cereal or administrated orally as drug to allow CD patients to consume gluten.

The oral delivery of preparations for treatment of CD is a matter of concern, since celiac inflammation starts in duodenal mucosa and a putative drug for this condition should be resistant to gastro-intestinal (GI) digestion to arrive unspoiled to the small intestine. p10-mer has been firstly identified in the peptic-tryptic digest of gluten (13). The gluten PT digestion performed in vitro mimics the proteolysis by human gastro-intestinal enzymes, therefore this finding demonstrates that p10-mer is resistant to the digestion by human GI system.

The results of the present study show that p10-mer peptide, can modulate the inflammatory response "in vitro", an important step to move towards new therapeutic strategies, based on the identification of "new targets" for a molecular innovative therapeutic approach. Turning off the inflammatory response, mediated by NF-kB, may in fact represent a key target in the immunotherapy of celiac disease.

**Author Contributions**

Conceived and designed the experiments: AC OV PG CF AP. Analyzed the data: AC OV FM VM M. Silano M. Sorice RM. Contributed reagents/materials/analysis tools: FM M. Silano M. Sorice RM. Wrote the paper: AC OV M. Silano M. Sorice RM.

**References**

1. Green PH, Collier C (2007) Celiac disease. N Engl J Med 357: 1731–1743.
2. Arentz-Hansen H, Korner R, Møllberg O, Quaasen H, Vader W, et al. (2000) The intestinal T cell response to α-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med 191: 603–612.
3. Camarca A, Anderson RP, Mamone G, Fiero O, Facchiano A, et al. (2009) Intestinal T Cell Responses to Gluten Peptides Are Largely Heterogeneous: Implications for a Peptide-Based Therapy in Celiac Disease. J Immunol 182: 4150–4166.
4. Hui S, Menton JI, Monteiro RC, Zhang S, Cellier C, et al. (2004) A direct role for NGK2D/MICA interaction in villous atrophy during celiac disease. Immunity 21: 367–377.
5. Barone MV, Gimmigliano A, Casteria G, Paletta G, Maurano F, et al. (2007) Growth factor-like activity of gliadin, an alimentary protein: implications for celiac disease. Gut 56: 480–488.
6. Cinova J, Palová-Jelíňková L, Smythies LE, Cerna´ M, Pecharova´ B, et al. (2007) Gliadin peptides activate blood monocytes from patients with celiac disease. J Clin Immunol 27: 201–209.
7. Jabri B, Solli dLM (2006) Mechanisms of disease: immunopathogenesis of celiac disease. Nat Clin Pract Gastroenterol Hepatol 3: 516–525.
8. Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Raia V, et al. (2005) Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterology 129: 1400–1413.
9. Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Raia V, et al. (2003) Association between innate response to gliadin and activation of pathogenic T cell in celiac disease. Lancet 362: 30–37.
10. Luciani A, Vellella VR, Vasturro A, Giudino I, Pettoello-Mantovani M, et al. (2010) Lysosomal accumulation of gliadin p31–43 peptide induces oxidative stress and tissue transglutaminase-mediated PPARγ downregulation in intestinal epithelial cells and coeliac mucosa. Gut 59: 311–319.
11. Sonner DI, Bailey SR, Schuster RM, Lentsch AB, Prits TA (2010) TNF-α induces vectorial secretion of IL-6 in Caco-2 cells. J Gastrointest Surg 14: 1392–1399.
12. Ghosh S, May MJ, Kopp EB (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225–260.
13. De Vincenzi M, Gasiarrini G, Silano V (1997) A small peptide from durum wheat gluten prevents cell agglutination induced by prolamins-peptides toxic in celiac disease. Toxicology 120: 207–213.
14. Silano M, Di Benedetto R, Maiatelli F, De Vincenti A, Calcattera R, et al. (2008) A 10-residue peptide from durum wheat promotes a shift from a Th1-type response toward a Th2-type response in celiac disease. Am J Clin Nutr 87: 415–423.
15. Silano M, Di Benedetto R, Trecce A, Arrabito G, Leopoldi F, et al. (2007) A decapetide from durum wheat prevents celiac peripheral blood lymphocytes activation by gliadin peptides. Peda’llar Res 61: 67–71.
16. Hidalgo J, Rass T, Borchart R (1989) Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96: 736–749.
17. De Rui G, Oecrosio P, Auricchio S, Gramenzi S, Morini G, et al. (1979) Toxicity of wheat flour proteins and protein-derived peptides for in vitro developing intestine from rat fetuses. Pediatr Res 131: 255–261.
18. Tsanakis C, Androulidaki A, Vehilaki M, Margioris AN (2006) Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 38: 1654–1661.
19. Vincentini O, Quarranta MG, Viswa M, Agostoni C, Silano M. (2011) Docosahexaenoic acid modulates in vitro the inflammation of celiac disease in intestinal epithelial cells via the inhibition of ePLA2. Clin Nutrition 30: 541–546.
20. Chow WL, Lee YK (2008) Free fatty acid is a danger signal to human intestinal epithelial cells. Br J Nutr 99: 445–454.
21. Lounie M, Ciacci C, Ricciardelli I, Vacca L, Quarratonio S, et al. (2005) Gliadin as a stimulus of innate responses in celiac disease. Mol Immunol 42: 913–918.
22. Lammers KM, Khandelwal S, Chaudhury F, Krzyzak D, Puppa EL, et al. (2011) Identification of a novel immunomodulatory gliadin peptide that causes interleukin-6 release in a celiac disease receptor CXCR3-dependent manner only in patients with celiac disease. Immunology 132: 432–440.
23. Hall RP, Benbenisty KM, Micc C, Takeuchi F, Strelive RN (2007) Serum IL-8 in patients with dermatitis herpetiformis is produced to dietary gluten. J Invest Dermatol 127: 2158–2163.
24. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, et al. (1999) A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104: 383–389.
25. Lavo B, Knutson L, Loof L, Hallgren R (1990) Gliadin challenge-induced jejunal prostaglandin E2 secretion in celiac disease. Gastroenterology 99: 703–707.
26. Martin-Veneo R, Rong-Peraa S, Ferrer R, Moreno J. (2006) Arachidonic acid cascade and epithelial barrier function during Caco-2 cell differentiation. J Lipid Res 47: 1416–1423.
27. De Vita P, Fico DBM, Luciani A, Vincentini O, Pettoello-Mantovani M, et al. (2012) A-esculin contained decamer shows a celiac disease prevention activity. J Cereal Sci 55: 234–242.
28. Gass J, Bethune MT, Sigel M, Spencer A, Khola G (2007) Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 133: 472–480.
29. Panier M, Veere EF, Nauser-Eddine M, David CS, Veizas A, et al. (2009) Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. Gastroenterology 136: 288–295.
30. Kelly CP, Green PH, Murray JA, Dimarino AJ, Colatella A, et al. (2013) Lactate acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther 37:252–262.
31. Pardini C, Pelletier JN, Lubell WD, Keillor JW (2008) Cinnamoyl inhibitors of tissue transglutaminase. J Org Chem 73: 5766–5775.
32. Siegel M, Xia J, Khosla C (2007) Structure-based design of alpha-amido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2. Bioorg Med Chem 15: 6253–6261.

33. Lerner A (2010) New therapeutic strategies for celiac disease. Autoimmun Rev 9: 144–147.

34. Salvati VM, Mazzarella G, Gianfrani C, Levings MK, Stefanile R, et al (2005) Recombinant human interleukin 10 suppresses gliadin dependent T cell activation in ex vivo cultured coeliac intestinal mucosa. Gut 54: 46–53.